Results 41 to 50 of about 68,738 (313)
PKM2 is not required for pancreatic ductal adenocarcinoma [PDF]
Cancer & Metabolism, 2018 While most cancer cells preferentially express the M2 isoform of the glycolytic enzyme pyruvate kinase (PKM2), PKM2 is dispensable for tumor development in several mouse cancer models. PKM2 is expressed in human pancreatic cancer, and there have been conflicting reports on the association of PKM2 expression and pancreatic cancer patient survival, but ...
Dolores Di Vizio +7 more
openaire +6 more sources
Features of immunophenotype of pancreatic ductal adenocarcinoma
Zaporožskij Medicinskij Žurnal, 2014 Aim. To determine features of immunophenotype of pancreatic ductal adenocarcinoma. Methods and results. At the immunohistochemical research of biopsy and postoperative material of 120 patients with pancreatic ductal adenocarcinoma the expression ...
A. V. Evseyev
doaj +1 more source
MicroRNAs in pancreatic ductal adenocarcinoma
World Journal of Gastroenterology, 2011 Ductal adenocarcinoma of the pancreas is a lethal cancer for which the only chance of long-term survival belongs to the patient with localized disease in whom a potentially curative resection can be done. Therefore, biomarkers for early detection and new therapeutic strategies are urgently needed.
Donghwa Kim +5 more
openaire +3 more sources
Preclinical models of pancreatic ductal adenocarcinoma [PDF]
The Journal of Pathology, 2015 AbstractPancreatic ductal adenocarcinoma (PDA) is one of the most difficult human malignancies to treat. The 5‐year survival rate of PDA patients is 7% and PDA is predicted to become the second leading cancer‐related cause of death in the USA. Despite intensive efforts, the translation of findings in preclinical studies has been ineffective, due ...
David A. Tuveson +6 more
openaire +7 more sources
Molecular Therapy: Nucleic Acids, 2022 This research developed an easy-to-use, reproducible pancreatic cancer animal model utilizing pancreas-targeted hydrodynamic gene delivery to deliver human pancreatic cancer-related genes to the pancreas of wild-type rats.
Osamu Shibata +12 more
doaj
Imaging for pancreatic ductal adenocarcinoma
Chinese Clinical Oncology, 2017 Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers worldwide due to its aggressiveness and the challenge to early diagnosis. Complete surgical resection is the only curative option, but fewer than 20% of patients have potentially resectable disease at the time of the diagnosis.
Davinia Ryan +4 more
openaire +3 more sources
Autophagy in cancer and protein conformational disorders
FEBS Letters, EarlyView.Autophagy plays a crucial role in numerous biological processes, including protein and organelle quality control, development, immunity, and metabolism. Hence, dysregulation or mutations in autophagy‐related genes have been implicated in a wide range of human diseases.
Sergio Attanasio
wiley +1 more source
Metabolism remodeling in pancreatic ductal adenocarcinoma [PDF]
Cell Stress, 2019 Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of death of patients with malignant cancers by 2030. Current options of PDAC treatment are limited and the five-year survival rate is less than 8%, leading to an urgent need to explore innovatively therapeutic strategies.
Yi-Ping Wang +3 more
openaire +4 more sources
Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells
Molecular Oncology, EarlyView.In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi +3 more
wiley +1 more source
The anti-tumor effect of HDAC inhibition in a human pancreas cancer model is significantly improved by the simultaneous inhibition of cyclooxygenase 2. [PDF]
PLoS ONE, 2013 Pancreatic ductal adenocarcinoma is the fourth leading cause of cancer death worldwide, with no satisfactory treatment to date. In this study, we tested whether the combined inhibition of cyclooxygenase-2 (COX-2) and class I histone deacetylase (HDAC ...
Olivier Peulen +6 more
doaj +1 more source